Articles Referencing HPTX

Hyperion Therapeutics prices IPO at $10.00, below the range

7/26/2012, 8:49 am from Renaissance Capital in News Headlines, IPOs

Hyperion Therapeutics, which is focused on the treatment of orphan diseases of the liver relating to the urea cycle, raised $50 million by offering 5 million shares at $10.00, below the range... Read >>

Biotech Hyperion Therapeutics sets terms for $50 million US IPO

7/13/2012, 8:21 am from Renaissance Capital in News Headlines, IPOs

Hyperion Therapeutics, a biotech focused on the treatment of urea cycle disorders and hepatic encephalopathy, announced terms for its IPO on Friday. The South San Francisco, CA-based... Read >>